U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4H3FN2O2
Molecular Weight 130.0774
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUOROURACIL

SMILES

c1c(c(nc(n1)O)O)F

InChI

InChIKey=GHASVSINZRGABV-UHFFFAOYSA-N
InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)

HIDE SMILES / InChI

Description
Curator's Comment:: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012209s040lbl.pdf

Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances from becoming incorporated into DNA during the "S" phase (of the cell cycle), stopping normal development and division. Fluorouracil blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand. Fluorouracil is used for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FLUOROURACIL

Approved Use

Fluorouracil is indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum Adenocarcinoma of the Breast Gastric Adenocarcinoma Pancreatic Adenocarcinoma

Launch Date

-242697600000
Primary
FLUOROURACIL

Approved Use

Fluorouracil is indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum Adenocarcinoma of the Breast Gastric Adenocarcinoma Pancreatic Adenocarcinoma

Launch Date

-242697600000
Primary
FLUOROURACIL

Approved Use

Fluorouracil is indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum Adenocarcinoma of the Breast Gastric Adenocarcinoma Pancreatic Adenocarcinoma

Launch Date

-242697600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
11.49 ng/mL
1 g 2 times / day steady-state, topical
dose: 1 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
FLUOROURACIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
278 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUOROURACIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
22.39 ng × h/mL
1 g 2 times / day steady-state, topical
dose: 1 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
FLUOROURACIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
205 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUOROURACIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.24 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUOROURACIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
90%
FLUOROURACIL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
DLT: Ataxia...
Other AEs: Anorexia, Nausea...
Dose limiting toxicities:
Ataxia (grade 3, 4 patients)
Other AEs:
Anorexia (3 patients)
Nausea (severe, 2 patients)
Vomiting (2 patients)
Stomatitis (severe, 1 patient)
Diarrhea (3 patients)
Weakness (1 patient)
Hair loss (1 patient)
Peeling (1 patient)
Sources:
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Other AEs: Ataxia, Anorexia...
Other AEs:
Ataxia (3 patients)
Anorexia (4 patients)
Nausea (severe, 2 patients)
Vomiting (3 patients)
Stomatitis (mild, 3 patients)
Diarrhea (2 patients)
Weakness (2 patients)
Hair loss (2 patients)
Loss of eyelashes (1 patient)
Peeling (2 patients)
Peeling (2 patients)
Sources:
2800 mg/m2 1 times / week multiple, intravenous
Dose: 2800 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2800 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3, 1 patient)
Sources:
3000 mg/m2 1 times / week multiple, intravenous
Dose: 3000 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3000 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3-4, 2 patients)
Sources:
3250 mg/m2 1 times / week multiple, intravenous
Dose: 3250 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3250 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3-4, 2 patients)
Sources:
0.5 % 1 times / day multiple, topical
Recommended
Dose: 0.5 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Disc. AE: Irritation skin...
AEs leading to
discontinuation/dose reduction:
Irritation skin (12%)
Sources:
1250 mg 1 times / 2 days multiple, oral
Dose: 1250 mg, 1 times / 2 days
Route: oral
Route: multiple
Dose: 1250 mg, 1 times / 2 days
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
500 mg single, oral
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Anaemia, Angina unstable...
Other AEs:
Anaemia (serious, 2 patients)
Angina unstable (serious, 5 patients)
Arrhythmia (serious, 2 patients)
Arteriosclerosis coronary artery (serious, 1 patient)
Atrial flutter (serious, 3 patients)
Atrial tachycardia (serious, 1 patient)
Atrial thrombosis (serious, 1 patient)
Cardiac disorder (serious, 1 patient)
Cardiac failure congestive (serious, 7 patients)
Cardio-respiratory arrest (serious, 2 patients)
Coronary artery stenosis (serious, 1 patient)
Myocardial ischaemia (serious, 1 patient)
Palpitations (serious, 1 patient)
Pericarditis (serious, 1 patient)
Ventricular tachycardia (serious, 2 patients)
Vertigo (serious, 1 patient)
Vertigo positional (serious, 1 patient)
Disorder vestibular (serious, 1 patient)
Goitre (serious, 1 patient)
Inappropriate antidiuretic hormone secretion (serious, 1 patient)
Abdominal hernia (serious, 1 patient)
Colitis ischaemic (serious, 1 patient)
Gastritis (serious, 2 patients)
Haemorrhoids (serious, 1 patient)
Impaired gastric emptying (serious, 1 patient)
Hernia inguinal (serious, 1 patient)
Intestinal obstruction (serious, 2 patients)
Obstruction gastric (serious, 1 patient)
Oesophageal obstruction (serious, 1 patient)
Pancreatitis (serious, 1 patient)
Vomiting (serious, 1 patient)
Adhesion (serious, 1 patient)
Chest discomfort (serious, 1 patient)
Generalised oedema (serious, 1 patient)
Non-cardiac chest pain (serious, 3 patients)
Cholelithiasis (serious, 2 patients)
Hepatitis alcoholic (serious, 1 patient)
Arthritis infective (serious, 1 patient)
Bacteraemia (serious, 1 patient)
Bronchopneumonia (serious, 1 patient)
Cholecystitis infective (serious, 1 patient)
Clostridium difficile infection (serious, 3 patients)
Cystitis (serious, 1 patient)
Endocarditis (serious, 1 patient)
Incision site cellulitis (serious, 1 patient)
Infection (serious, 2 patients)
Septic shock (serious, 1 patient)
Upper respiratory tract infection (serious, 1 patient)
Urinary tract infection (serious, 6 patients)
Viral infection (serious, 1 patient)
Device toxicity (serious, 1 patient)
Fall (serious, 11 patient)
Hip fracture (serious, 2 patients)
Intentional overdose (serious, 1 patient)
Limb injury (serious, 1 patient)
Lower limb fracture (serious, 1 patient)
Meniscus injury (serious, 2 patients)
Periprosthetic fracture (serious, 1 patient)
Postoperative fever (serious, 1 patient)
Procedural nausea (serious, 1 patient)
Procedural pain (serious, 1 patient)
Radiation oesophagitis (serious, 1 patient)
Road traffic accident (serious, 2 patients)
Traumatic haematoma (serious, 1 patient)
Vascular bypass dysfunction (serious, 1 patient)
Blood glucose increased (serious, 1 patient)
Electrocardiogram abnormal (serious, 1 patient)
Haemoglobin decreased (serious, 1 patient)
International normalised ratio increased (serious, 2 patients)
White blood cell count increased (serious, 1 patient)
Dehydration (serious, 5 patients)
Diabetes mellitus inadequate control (serious, 2 patients)
Failure to thrive (serious, 3 patients)
Hyperglycaemia (serious, 2 patients)
Hyponatraemia (serious, 3 patients)
Iron deficiency (serious, 1 patient)
Arthralgia (serious, 3 patients)
Bursa disorder (serious, 1 patient)
Exostosis (serious, 1 patient)
Muscular weakness (serious, 1 patient)
Osteoarthritis (serious, 10 patients)
Tendonitis (serious, 1 patient)
Basal cell carcinoma (serious, 1 patient)
Benign salivary gland neoplasm (serious, 1 patient)
Brain neoplasm (serious, 2 patients)
Colorectal cancer (serious, 1 patient)
Diffuse large B-cell lymphoma stage IV (serious, 1 patient)
Haemangioma (serious, 1 patient)
Lung neoplasm malignant (serious, 4 patients)
Malignant melanoma (serious, 3 patients)
Metastases to central nervous system (serious, 1 patient)
Metastatic squamous cell carcinoma (serious, 1 patient)
Neuroendocrine carcinoma (serious, 1 patient)
Prostate cancer (serious, 5 patients)
Prostate cancer recurrent (serious, 1 patient)
Renal cancer (serious, 2 patients)
Renal cancer metastatic (serious, 1 patient)
Renal cell carcinoma (serious, 1 patient)
Salivary gland cancer (serious, 1 patient)
Squamous cell carcinoma (serious, 2 patients)
Basilar artery stenosis (serious, 1 patient)
Cognitive disorder (serious, 1 patient)
Dementia (serious, 4 patients)
Epilepsy (serious, 1 patient)
Headache (serious, 1 patient)
Hypoaesthesia (serious, 1 patient)
Parkinson's disease (serious, 2 patients)
Haemorrhage subarachnoid (serious, 1 patient)
Transient ischaemic attack (serious, 4 patients)
Transient ischaemic attack (serious, 4 patients)
Dementia vascular (serious, 1 patient)
Alcohol abuse (serious, 2 patients)
Binge drinking (serious, 1 patient)
Completed suicide (serious, 1 patient)
Confusional state (serious, 1 patient)
Delirium tremens (serious, 1 patient)
Depression (serious, 3 patients)
Mental disorder (serious, 1 patient)
Mental status changes (serious, 2 patients)
Post-traumatic stress disorder (serious, 1 patient)
Suicidal behaviour (serious, 1 patient)
Suicidal ideation (serious, 3 patients)
Hydronephrosis (serious, 2 patients)
Nephropathy (serious, 1 patient)
Renal failure chronic (serious, 1 patient)
Erectile dysfunction (serious, 1 patient)
Prostatic haemorrhage (serious, 1 patient)
Prostatitis (serious, 1 patient)
Chronic obstructive pulmonary disease (serious, 9 patients)
Dyspnoea (serious, 2 patients)
Dyspnoea exertional (serious, 1 patient)
Haemoptysis (serious, 1 patient)
Pleural effusion (serious, 1 patient)
Pulmonary embolism (serious, 3 patients)
Respiratory failure (serious, 1 patient)
Rash (serious, 1 patient)
Angioplasty (serious, 1 patient)
Cholecystectomy (serious, 1 patient)
Coronary angioplasty (serious, 1 patient)
Elective procedure (serious, 1 patient)
Hip arthroplasty (serious, 1 patient)
Knee arthroplasty (serious, 1 patient)
Medical device removal (serious, 1 patient)
Oesophagogastric fundoplasty (serious, 1 patient)
Parotidectomy (serious, 1 patient)
Wound treatment (serious, 1 patient)
Aortic aneurysm (serious, 2 patients)
Aortic occlusion (serious, 1 patient)
Arterial occlusive disease (serious, 1 patient)
Femoral artery occlusion (serious, 1 patient)
Labile hypertension (serious, 1 patient)
Orthostatic hypotension (serious, 2 patients)
Disorder peripheral vascular (serious, 1 patient)
Lymphadenopathy (below serious, 1 patient)
Vertigo (below serious, 1 patient)
Adrenal mass (below serious, 1 patient)
Eye haemorrhage (below serious, 1 patient)
Eye irritation (below serious, 3 patients)
Eye pain (below serious, 2 patients)
Eye pruritus (below serious, 1 patient)
Eye swelling (below serious, 4 patients)
Photophobia (below serious, 1 patient)
Visual acuity reduced (below serious, 1 patient)
Abdominal pain upper (below serious, 2 patients)
Cheilitis (below serious, 1 patient)
Diarrhoea (below serious, 3 patients)
Diverticulum (below serious, 1 patient)
Dyspepsia (below serious, 1 patient)
Gastrooesophageal reflux disease (below serious, 1 patient)
Gingival pain (below serious, 1 patient)
Nausea (below serious, 5 patients)
Fatigue (below serious, 3 patients)
Feeling of body temperature change (below serious, 1 patient)
Hernia (below serious, 1 patient)
Local swelling (below serious, 1 patient)
Malaise (below serious, 1 patient)
Pain (below serious, 11 patient)
Syringe issue (below serious, 1 patient)
Temperature intolerance (below serious, 1 patient)
Tenderness (below serious, 2 patients)
Vessel puncture site haematoma (below serious, 1 patient)
Hypersensitivity (below serious, 1 patient)
Seasonal allergy (below serious, 1 patient)
Bronchitis (below serious, 4 patients)
Cellulitis (below serious, 1 patient)
Folliculitis (below serious, 1 patient)
Fungal infection (below serious, 1 patient)
Herpes zoster (below serious, 2 patients)
Infection (below serious, 2 patients)
Influenza (below serious, 1 patient)
Nasopharyngitis (below serious, 5 patients)
Oral herpes (below serious, 1 patient)
Pneumonia (below serious, 2 patients)
Accidental exposure to product (below serious, 1 patient)
Arthropod sting (below serious, 1 patient)
Fall (below serious, 5 patients)
Laceration (below serious, 1 patient)
Muscle rupture (below serious, 1 patient)
Body temperature increased (below serious, 1 patient)
Emergency care examination (below serious, 1 patient)
Gout (below serious, 1 patient)
Arthralgia (below serious, 1 patient)
Back pain (below serious, 3 patients)
Foot deformity (below serious, 1 patient)
Musculoskeletal pain (below serious, 1 patient)
Neck pain (below serious, 1 patient)
Pain in extremity (below serious, 1 patient)
Polymyalgia rheumatica (below serious, 1 patient)
Basal cell carcinoma (below serious, 1 patient)
Haemangioma (below serious, 1 patient)
Transitional cell carcinoma (below serious, 1 patient)
Burning sensation (below serious, 1 patient)
Dizziness (below serious, 4 patients)
Headache (below serious, 5 patients)
Hypoaesthesia (below serious, 2 patients)
Syncope (below serious, 1 patient)
Tunnel vision (below serious, 1 patient)
Abnormal dreams (below serious, 1 patient)
Anxiety (below serious, 1 patient)
Psychotic disorder (below serious, 1 patient)
Sleep disorder (below serious, 22 patients)
Dysuria (below serious, 1 patient)
Haemorrhage urinary tract (below serious, 1 patient)
Pollakiuria (below serious, 1 patient)
Chronic obstructive pulmonary disease (below serious, 1 patient)
Nasal congestion (below serious, 1 patient)
Productive cough (below serious, 1 patient)
Pulmonary mass (below serious, 1 patient)
Rhinorrhoea (below serious, 1 patient)
Sinus disorder (below serious, 1 patient)
Acne (below serious, 5 patients)
Blister (below serious, 2 patients)
Blood blister (below serious, 1 patient)
Decubitus ulcer (below serious, 1 patient)
Dermatitis (below serious, 447 patients)
Dermatitis allergic (below serious, 1 patient)
Hyperhidrosis (below serious, 2 patients)
Photosensitivity reaction (below serious, 5 patients)
Post inflammatory pigmentation change (below serious, 1 patient)
Scab (below serious, 1 patient)
Seborrhoea (below serious, 1 patient)
Dermatitis seborrhoeic (below serious, 2 patients)
Skin discomfort (below serious, 1 patient)
Skin haemorrhage (below serious, 3 patients)
Skin tightness (below serious, 1 patient)
Skin ulcer (below serious, 1 patient)
Urticaria (below serious, 1 patient)
Oral surgery (below serious, 1 patient)
Wound drainage (below serious, 1 patient)
Haemorrhage (below serious, 7 patients)
Temporal arteritis (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hair loss 1 patient
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Peeling 1 patient
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Weakness 1 patient
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Vomiting 2 patients
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Anorexia 3 patients
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Diarrhea 3 patients
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Ataxia grade 3, 4 patients
DLT, Disc. AE
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Stomatitis severe, 1 patient
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Nausea severe, 2 patients
3400 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 3400 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3400 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Loss of eyelashes 1 patient
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Diarrhea 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Hair loss 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Peeling 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Peeling 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Weakness 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Ataxia 3 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Vomiting 3 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Anorexia 4 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Stomatitis mild, 3 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Nausea severe, 2 patients
2600 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2600 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2600 mg/m2, 1 times / week
Sources:
unhealthy, 54 years (range: 24-78 years)
Health Status: unhealthy
Age Group: 54 years (range: 24-78 years)
Sex: M+F
Sources:
Diarrhea grade 3, 1 patient
DLT
2800 mg/m2 1 times / week multiple, intravenous
Dose: 2800 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2800 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
Diarrhea grade 3-4, 2 patients
DLT
3000 mg/m2 1 times / week multiple, intravenous
Dose: 3000 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3000 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
Diarrhea grade 3-4, 2 patients
DLT
3250 mg/m2 1 times / week multiple, intravenous
Dose: 3250 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 3250 mg/m2, 1 times / week
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: M+F
Sources:
Irritation skin 12%
Disc. AE
0.5 % 1 times / day multiple, topical
Recommended
Dose: 0.5 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Abnormal dreams below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Accidental exposure to product below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Adrenal mass below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Anxiety below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arthralgia below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arthropod sting below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Basal cell carcinoma below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Blood blister below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Body temperature increased below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Burning sensation below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cellulitis below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cheilitis below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Chronic obstructive pulmonary disease below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Decubitus ulcer below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dermatitis allergic below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diverticulum below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspepsia below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dysuria below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Emergency care examination below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Eye haemorrhage below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Eye pruritus below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Feeling of body temperature change below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Folliculitis below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Foot deformity below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fungal infection below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Gastrooesophageal reflux disease below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Gingival pain below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Gout below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemangioma below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemorrhage urinary tract below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hernia below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypersensitivity below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Influenza below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Laceration below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Local swelling below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Lymphadenopathy below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Malaise below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Muscle rupture below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Musculoskeletal pain below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nasal congestion below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Neck pain below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oral herpes below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oral surgery below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pain in extremity below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Photophobia below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pollakiuria below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Polymyalgia rheumatica below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Post inflammatory pigmentation change below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Productive cough below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Psychotic disorder below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pulmonary mass below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Rhinorrhoea below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Scab below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Seasonal allergy below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Seborrhoea below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Sinus disorder below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Skin discomfort below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Skin tightness below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Skin ulcer below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Syncope below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Syringe issue below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Temperature intolerance below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Temporal arteritis below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Transitional cell carcinoma below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Tunnel vision below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Urticaria below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vertigo below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vessel puncture site haematoma below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Visual acuity reduced below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Wound drainage below serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pain below serious, 11 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Abdominal pain upper below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Blister below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dermatitis seborrhoeic below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Eye pain below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Herpes zoster below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hyperhidrosis below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypoaesthesia below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Infection below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pneumonia below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Tenderness below serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Sleep disorder below serious, 22 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Back pain below serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diarrhoea below serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Eye irritation below serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fatigue below serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Skin haemorrhage below serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Bronchitis below serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness below serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Eye swelling below serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dermatitis below serious, 447 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Acne below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fall below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Headache below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nasopharyngitis below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nausea below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Photosensitivity reaction below serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemorrhage below serious, 7 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Abdominal hernia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Adhesion serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Angioplasty serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Aortic occlusion serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arterial occlusive disease serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arteriosclerosis coronary artery serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arthritis infective serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Atrial tachycardia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Atrial thrombosis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Bacteraemia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Basal cell carcinoma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Basilar artery stenosis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Benign salivary gland neoplasm serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Binge drinking serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Blood glucose increased serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Bronchopneumonia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Bursa disorder serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cardiac disorder serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Chest discomfort serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cholecystectomy serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cholecystitis infective serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cognitive disorder serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Colitis ischaemic serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Colorectal cancer serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Completed suicide serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Confusional state serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Coronary angioplasty serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Coronary artery stenosis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cystitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Delirium tremens serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dementia vascular serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Device toxicity serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diffuse large B-cell lymphoma stage IV serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Disorder peripheral vascular serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Disorder vestibular serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspnoea exertional serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Elective procedure serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Electrocardiogram abnormal serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Endocarditis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Epilepsy serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Erectile dysfunction serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Exostosis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Femoral artery occlusion serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Generalised oedema serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Goitre serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemangioma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemoglobin decreased serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemoptysis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemorrhage subarachnoid serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemorrhoids serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Headache serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hepatitis alcoholic serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hernia inguinal serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hip arthroplasty serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypoaesthesia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Impaired gastric emptying serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Inappropriate antidiuretic hormone secretion serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Incision site cellulitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Intentional overdose serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Iron deficiency serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Knee arthroplasty serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Labile hypertension serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Limb injury serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Lower limb fracture serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Medical device removal serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Mental disorder serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Metastases to central nervous system serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Metastatic squamous cell carcinoma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Muscular weakness serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Myocardial ischaemia serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nephropathy serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Neuroendocrine carcinoma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Obstruction gastric serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oesophageal obstruction serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oesophagogastric fundoplasty serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Palpitations serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pancreatitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Parotidectomy serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pericarditis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Periprosthetic fracture serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pleural effusion serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Post-traumatic stress disorder serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Postoperative fever serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Procedural nausea serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Procedural pain serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Prostate cancer recurrent serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Prostatic haemorrhage serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Prostatitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Radiation oesophagitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Rash serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Renal cancer metastatic serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Renal cell carcinoma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Renal failure chronic serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Respiratory failure serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Salivary gland cancer serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Septic shock serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Suicidal behaviour serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Tendonitis serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Traumatic haematoma serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Upper respiratory tract infection serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vascular bypass dysfunction serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vertigo positional serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vertigo serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Viral infection serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vomiting serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
White blood cell count increased serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Wound treatment serious, 1 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Osteoarthritis serious, 10 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fall serious, 11 patient
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Alcohol abuse serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Anaemia serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Aortic aneurysm serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arrhythmia serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Brain neoplasm serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cardio-respiratory arrest serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cholelithiasis serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diabetes mellitus inadequate control serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspnoea serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Gastritis serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hip fracture serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hydronephrosis serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hyperglycaemia serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Infection serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
International normalised ratio increased serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Intestinal obstruction serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Meniscus injury serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Mental status changes serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Orthostatic hypotension serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Parkinson's disease serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Renal cancer serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Road traffic accident serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Squamous cell carcinoma serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Ventricular tachycardia serious, 2 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arthralgia serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Atrial flutter serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Clostridium difficile infection serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Depression serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Failure to thrive serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hyponatraemia serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Malignant melanoma serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Non-cardiac chest pain serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pulmonary embolism serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Suicidal ideation serious, 3 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dementia serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Lung neoplasm malignant serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Transient ischaemic attack serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Transient ischaemic attack serious, 4 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Angina unstable serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dehydration serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Prostate cancer serious, 5 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Urinary tract infection serious, 6 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cardiac failure congestive serious, 7 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Chronic obstructive pulmonary disease serious, 9 patients
5 % 2 times / day steady, topical
Dose: 5 %, 2 times / day
Route: topical
Route: steady
Dose: 5 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
2001
The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer.
2001
Thymidine labeling index analysis in early breast cancer patients randomized to receive perioperative chemotherapy.
2001
Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
2001
Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer.
2001
Gemcitabine: progress in the treatment of pancreatic cancer.
2001
Phase II study of combined 5-fluorouracil/ Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer.
2001 Feb
Quantitative short-term study of anal sphincter function after chemoradiation for rectal cancer.
2001 Feb
Adenocarcinoma of the ethmoidal sinus complex: surgical debulking and topical fluorouracil may be the optimal treatment.
2001 Feb
Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma.
2001 Feb
Immunomodulation by anticancer chemotherapy: more is not always better (review).
2001 Feb
Analysis of uracil DNA glycosylase in human colorectal cancer.
2001 Feb
Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer.
2001 Feb
Reconstitution of liver mass via cellular hypertrophy in the rat.
2001 Feb
Effect of a mutant form of IkappaB-alpha on 5-fluorouracil-induced apoptosis in transformed human salivary gland cells.
2001 Feb
Thrombopoietin signaling is required for in vivo expansion of IL-11--responsive hematopoietic progenitor cells in the steady state.
2001 Feb
Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?
2001 Feb
In vivo evaluation of a novel antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation.
2001 Feb 1
A randomized Phase II trial in patients with carcinoma of an unknown primary site.
2001 Feb 1
Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy.
2001 Feb 1
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
2001 Feb 1
Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay.
2001 Feb 1
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
2001 Feb 1
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
2001 Feb 1
E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors.
2001 Feb 10
Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.
2001 Feb 15
Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
2001 Feb 15
Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.
2001 Feb 15
Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil.
2001 Feb 15
Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP.
2001 Feb 2
Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line.
2001 Feb 9
Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator.
2001 Jan
Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.
2001 Jan
Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer.
2001 Jan
Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer.
2001 Jan
Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
2001 Jan
Retroviral expression of Escherichia coli thymidylate synthase cDNA confers high-level antifolate resistance to hematopoietic cells.
2001 Jan 1
Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer.
2001 Jan 1
Comparison of the malignant phenotype and genotype of the human androgen-independent cell line DU 145 and a subline derived from metastasis after orthotopic implantation in nude mice.
2001 Jan 15
Hydroxylamine-containing inhibitors of polyamine biosynthesis and impairment of colon cancer cell growth.
2001 Jan 15
Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase.
2001 Jan 15
Monohydroxylation and esterification as determinants of the effects of cis- and trans-9-octadecenoic acids on the permeation of hydrocortisone and 5-fluorouracil across hairless mouse skin in vitro.
2001 Jan 16
Discoid lupus erythematosus (DLE)-like lesion induced by uracil-tegafur (UFT).
2001 Jan-Feb
Oxaliplatin: a new agent for colorectal cancer.
2001 Mar
Therapeutic approaches to metastasis confined to the liver.
2001 Mar
Determinants of prognosis and response to therapy in colorectal cancer.
2001 Mar
Adjuvant chemotherapy for colon cancer.
2001 Mar
Impact on survival of surgery after concomitant chemoradiotherapy for locally advanced cancers of the esophagus.
2001 Mar 1
Antioxidants enhance the susceptibility of colon carcinoma cells to 5-fluorouracil by augmenting the induction of the bax protein.
2001 Mar 10
Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line.
2001 Mar-Apr
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Fluorouracil is recommended for administration either as an intravenous bolus or as an intravenous infusion, but may also be used topically http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
Recommended Dosage for Adenocarcinoma of the Colon and Rectum:
Route of Administration: Intravenous
Fluorouracil treatment (0.4uM) inhibited LXA4 secretion in colorectal cancer RKO cells
Name Type Language
FLUOROURACIL
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
2,4(1H,3H)-PYRIMIDINEDIONE, 5-FLUORO-
Systematic Name English
ADRUCIL
Brand Name English
FLUOROURACILUM [WHO-IP LATIN]
Common Name English
5-FU
Code English
PHTHORURACIL
Common Name English
5-FLUOROURACIL [IARC]
Common Name English
EMTRICITABINE IMPURITY F [WHO-IP]
Common Name English
QUEROPLEX
Common Name English
EFUDEX
Brand Name English
5-FLUOROPYRIMIDIN-2,4(1H,3H)-DIONE [WHO-IP]
Systematic Name English
5-FLUORURACIL
Common Name English
FLUOROURACIL [ORANGE BOOK]
Common Name English
FLUOROURACIL [EP MONOGRAPH]
Common Name English
5 FU
Code English
CARAC
Brand Name English
TOLAK
Systematic Name English
RO-29757
Code English
FLUOROURICIL
Common Name English
FLUOROURACIL [MI]
Common Name English
RO-2-9757
Code English
FLUOROURACIL [USP-RS]
Common Name English
5-FLUOROURACIL
WHO-IP  
Systematic Name English
FLUOROURACIL [VANDF]
Common Name English
5 FLUOROURACIL
Systematic Name English
FLUOROURACIL [WHO-DD]
Common Name English
FLUOROURACIL [USAN]
Common Name English
FLUCYTOSINE IMPURITY A [EP]
Common Name English
FLUCYTOSINE IMPURITY A [WHO-IP]
Common Name English
FLUOROURACIL [WHO-IP]
Common Name English
FLUOROURACIL [JAN]
Common Name English
NSC-19893
Code English
RO 2-9757
Code English
FLUOROURACIL [HSDB]
Common Name English
5-FLUOROURACIL [WHO-IP]
Common Name English
FLUOROURACIL [MART.]
Common Name English
5-FLUORO-URACIL
Systematic Name English
FLUOROURACIL [USP MONOGRAPH]
Common Name English
FLUOROURACIL [INN]
Common Name English
FLUOROPLEX
Brand Name English
Classification Tree Code System Code
LIVERTOX 423
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
NCI_THESAURUS C1557
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
WHO-ATC L01BC02
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
IARC 5-Fluorouracil
FDA ORPHAN DRUG 40589
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 13.4
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
WHO-ATC L01BC52
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
FDA ORPHAN DRUG 42289
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
WHO-VATC QL01BC02
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
NDF-RT N0000000233
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
NCI_THESAURUS C2021
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
WHO-VATC QL01BC52
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
EU-Orphan Drug EU/3/00/004
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
FDA ORPHAN DRUG 32088
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
NDF-RT N0000175595
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
FDA ORPHAN DRUG 131799
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
Code System Code Type Description
MERCK INDEX
M5483
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY Merck Index
FDA UNII
U3P01618RT
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
WIKIPEDIA
FLUOROURACIL
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-085-6
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
FLUOROURACIL
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY Description: A white or almost white, crystalline powder. Solubility: Sparingly soluble in water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Cytotoxic drug. Storage: Fluorouracil should be kept in a tightly closed container, protected from light. Additional information: Fluorouracil melts at about 282?C with decomposition. CAUTION: Fluorouracil must be handled with care, avoiding contact with the skin and inhalation of airborne particles. Definition: Fluorouracil contains not less than 98.5% and not more than 101.0% of C4H3FN2O2, calculated with reference to the dried substance.
MESH
D005472
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
DRUG CENTRAL
26
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
ChEMBL
CHEMBL185
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
NCI_THESAURUS
C505
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
EVMPD
SUB07721MIG
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
PUBCHEM
3385
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
EPA CompTox
51-21-8
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
USP_CATALOG
1279000
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY USP-RS
HSDB
3228
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
IUPHAR
4789
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
RXCUI
4492
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY RxNorm
LACTMED
Fluorouracil
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
CAS
51-21-8
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
INN
1421
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY
DRUG BANK
DB00544
Created by admin on Fri Jun 25 20:53:58 UTC 2021 , Edited by admin on Fri Jun 25 20:53:58 UTC 2021
PRIMARY